0000950170-24-026779.txt : 20240305 0000950170-24-026779.hdr.sgml : 20240305 20240305211458 ACCESSION NUMBER: 0000950170-24-026779 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Maduck Sean CENTRAL INDEX KEY: 0001698310 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50679 FILM NUMBER: 24724115 MAIL ADDRESS: STREET 1: C/O CORCEPT THERAPEUTICS INCORPORATED STREET 2: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC CENTRAL INDEX KEY: 0001088856 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 770487658 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650.688.8803 MAIL ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 ownership.xml 4 X0508 4 2024-03-01 0001088856 CORCEPT THERAPEUTICS INC CORT 0001698310 Maduck Sean C/O CORCEPT THERAPEUTICS INCORPORATED 149 COMMONWEALTH DRIVE MENLO PARK CA 94025 false true false false See Remarks false Common Stock 2024-03-01 4 F false 505 24.06 D 73950 D Common Stock 2024-03-01 4 A false 636 24.06 A 74586 D Common Stock 2024-03-01 4 A false 636 0.00 A 75222 D Common Stock 10000 I See Footnote Common Stock 10000 I See Footnote These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. Includes 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on March 1, 2024. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission. /s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck 2024-03-05